Microbiome: Accelerating Innovation and Development (MAID) Hub Project

Accelerating the development and delivery of next‑generation microbiome products.
Eligibility United Kingdom
Gabriela Henriques

Gabriela Henriques

Senior Scientist - Microbial Upstream

Connect
Funded by
University-of-Liverpool

What is MAID?

Microbiome bioproducts are rapidly reshaping global health, with applications ranging from cancer therapeutics to next‑generation antimicrobials like bacteriophages, as well as agricultural, nutraceutical and veterinary innovations. Yet despite their potential, innovators still face significant scientific and commercial barriers that slow progress and prevent many microbiome breakthroughs from reaching the market. 

MAID is a strategic collaboration led by the University of Liverpool, established to overcome these barriers and unlock the commercial potential of microbiome products, antimicrobial therapies, and diagnostic innovations across the Liverpool City Region (LCR) and throughout the UK. It provides bespoke, end-to-end support to help businesses navigate the complexities of product development, ensuring novel solutions in therapies and diagnostics reach the market faster. 

This one-stop-shop is built on the combined expertise of: 

- The University of Liverpool’s Microbiome Innovation Centre (MIC): Providing world-class scientific expertise, research capabilities, and access to unique facilities in microbiome science. 

- CPI: Leveraging our expertise in scaling up bioprocesses, manufacturing de-risking, and technology commercialisation to bridge the gap between lab-scale innovation and industrial reality. 

This project is part of the LCR Life Sciences Innovation Zone Programme* with the aim of supporting organisations in developing their microbiome technology across the UK. The project also underscores the region’s commitment to supporting high-growth SMEs in the life sciences sector.

*The Liverpool City Region Life Sciences Innovation Zone Programme forms part of the Government’s national Investment Zone Programme, positioning the city region as a powerhouse for health and life sciences innovation.

MAID progreamme

What MAID offers

MAID offers targeted support to help innovators progress microbiome and phage‑based innovations, including:

Expert advisory and strategic support 

Expert advisory and strategic support

  • Scientific consultancy, including expert input into experimental design and proof-of-principle. 
  • Technical roadmap for a comprehensive product development and manufacturing strategy. 
  • Commercial strategy, including market analysis, grant support and collaboration opportunities.
Facility access 

Facility access

  • Advanced facilities: access to state-of-the-art facilities and biomanufacturing scale-up capabilities. 
  • On-site support to guide development and/​or technology scale-up. 
  • Skills development: high-quality training, both scientific and commercial. 
Events 

Events

  • Networking opportunities.
  • Online webinars.
  • Strategic innovation workshops. 

For more details on events, check the Events section below. 

Engagement benefits

Working with MAID gives you access to a range of benefits, including:

Technology development

Accelerated translation

Comprehensive end-to-end solutions

Strategic engagement and signposting

Building connections

Funding by LCRCA

Events

Our events include training sessions, in-person workshops, and networking opportunities, bringing together industry to tackle common challenges and build a community of growth within microbiome sciences.

26 March 2026 — Online training — Scaling Microbiome Innovations: A Practical Guide to Process Development 

26 March 2026 — Online training — Scaling Microbiome Innovations: A Practical Guide to Process Development

Happening on 26 March 2026, this is a one‑day online training that covers the essential principles of process development for microbiome products. This session will allow the innovators to learn the essential process‑development principles that make technologies scalable, compliant, and ready for manufacturing.

Learn more and register here.

6 May 2026 — In-person workshop — Translating Innovation: Pathways for Next-Generation AMR Therapeutics 

6 May 2026 — In-person workshop — Translating Innovation: Pathways for Next-Generation AMR Therapeutics

The science is moving fast. The pathways to market are not.​Antimicrobial resistance demands bold innovation, but phages, engineered probiotics, recombinant proteins, and vaccines still face major hurdles on the road to real-world impact.

Happening in Liverpool on 6 May 2026, this one-day workshop brings together leaders from across the AMR ecosystem to tackle the practical barriers slowing translation and to define clearer, faster routes to market.

Why attend?
Because innovation without implementation won’t solve AMR.​This is where science, regulation, and commercialisation align.

What the day will cover:
-
Expanding the AMR therapeutic toolkit.
- Targeted protein and antibody strategies.
- Next-generation microbial therapeutics.​
- Vaccines for AMR.
- One health strategies for AMR therapeutics.

Learn more and register here.

How to get involved

We’re committed to supporting innovators progress their technologies, particularly in today’s challenging funding landscape. 

Contact us to find out how we can help accelerate your product development journey and move your innovation closer to market.

For more information

Gabriela Henriques

Gabriela Henriques

Senior Scientist - Microbial Upstream

Connect
CPI is your innovation partner to make your ideas a reality.